Novartis-Dr Reddy’s Sales Pact, Job Cuts: Are Foreign Firms Altering India Push?
Novartis India To Let Go Of About 400 Employees
Executive Summary
Novartis India hands over sales and distribution of certain established brands, accounting for 50% of the 2020-2021 product revenues, to Dr Reddy’s as more foreign firms opt to leverage ground strengths of local players. Does it represent a wider trend where foreign firms are re-calibrating operations in India to focus energies on specialty and patented products?
You may also be interested in...
Asia Deal Watch: Juniper Licenses Asia-Pacific-Plus Rights To Kolon’s Osteoarthritis Cell Therapy
Plus deals involving Shionogi/NEC, Ji Xing/LENZ, Kyowa Kirin/Ardelyx, CR Pharma/Everest Medicine and Dr Reddy’s/Novartis.
Foreign Firms Not Fatigued In India, Game For 'New Things'
Senior management executives of Roche, Bayer, AstraZeneca, Pfizer and Novo Nordisk in India signal momentum in product launch and clinical trial activity, belying apprehension of wider cutbacks by foreign firms in the country, though one executive stressed that “tried and tested models” may not work in the largely self-pay market.
Asia Deal Watch: Huadong Licenses Two Cancer ADCs From Heidelberg Pharma
German firm’s antibody-drug conjugates use amanitin payload. Plus deals involving Sanwa Kagaku/Crinetics, Takeda/Code Bio, Taro/Alchemee, Mankind/Dr. Reddy’s and more.